Lopinavir/Ritonavir Mylan European Union - English - EMA (European Medicines Agency)

lopinavir/ritonavir mylan

mylan s.a.s. - lopinavir/ritonavir - hiv infections - antivirals for systemic use, - lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infected adults, adolescents and children above the age of 2 years.the choice of lopinavir/ritonavir to treat protease inhibitor experienced hiv-1 infected patients should be based on individual viral resistance testing and treatment history of patients.

Potassium iodide G.L. Pharma 65 mg tablets Ireland - English - HPRA (Health Products Regulatory Authority)

potassium iodide g.l. pharma 65 mg tablets

g.l. pharma gmbh - potassium iodide - tablet - 65 milligram(s) - antidotes; potassium iodide

Potassium iodide G.L. Pharma 65mg Tablets Malta - English - Medicines Authority

potassium iodide g.l. pharma 65mg tablets

g.l. pharma gmbh schlossplatz 1, 8502 lannach, austria - potassium iodide - tablet - potassium iodide 65 mg - all other therapeutic products

Potassium Chloride 0.15% w/v & Glucose 5% w/v Solution for Infusion Ireland - English - HPRA (Health Products Regulatory Authority)

potassium chloride 0.15% w/v & glucose 5% w/v solution for infusion

fresenius kabi limited - potassium chloride; glucose monohydrate - solution for infusion - 0.15 + 5 percent weight/volume - solutions affecting the electrolyte balance; electrolytes with carbohydrates - blood substitutes and perfusion solutions; electrolytes with carbohydrates - prevention and treatment of potassium depletion and/or hypokalaemia in cases where supply of water and carbohydrates is required due to either restriction of the intake of fluids and electrolytes or depletion by normal routes

Potassium Chloride 0.3% w/v & Glucose 5% w/v Solution for Infusion Ireland - English - HPRA (Health Products Regulatory Authority)

potassium chloride 0.3% w/v & glucose 5% w/v solution for infusion

fresenius kabi limited - potassium chloride; glucose monohydrate - solution for infusion - 0.3 + 5 percent weight/volume - solutions affecting the electrolyte balance; electrolytes with carbohydrates - blood substitutes and perfusion solutions; electrolytes with carbohydrates - prevention and treatment of potassium depletion and/or hypokalaemia in cases where supply of water and carbohydrates is required due to either restriction of the intake of fluids and electrolytes or depletion by normal routes.

Potassium Chloride 0.15% w/v & Sodium Chloride 0.9% w/v Solution for Infusion Ireland - English - HPRA (Health Products Regulatory Authority)

potassium chloride 0.15% w/v & sodium chloride 0.9% w/v solution for infusion

fresenius kabi limited - potassium chloride; sodium chloride - solution for infusion - 0.15% w/v + 0.9% w/v percent weight/volume - solutions affecting the electrolyte balance; electrolytes

Potassium Chloride 0.3% w/v & Sodium Chloride 0.9% w/v Solution for Infusion Ireland - English - HPRA (Health Products Regulatory Authority)

potassium chloride 0.3% w/v & sodium chloride 0.9% w/v solution for infusion

fresenius kabi limited - potassium chloride; sodium chloride - solution for infusion - 0.3% w/v + 0.9% w/v percent weight/volume - solutions affecting the electrolyte balance; electrolytes

Ganfort European Union - English - EMA (European Medicines Agency)

ganfort

allergan pharmaceuticals ireland - bimatoprost, timolol - glaucoma, open-angle, ocular hypertension - ophthalmologicals, - reduction of intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.

Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva European Union - English - EMA (European Medicines Agency)

efavirenz/emtricitabine/tenofovir disoproxil zentiva

zentiva k.s. - efavirenz, emtricitabine, tenofovir disoproxil, phosphate - hiv infections - antivirals for systemic use, - efavirenz/emtricitabine/tenofovir disoproxil zentiva is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. it is indicated for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adults aged 18 years and over with virologic suppression to hiv-1 rna levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in efavirenz/emtricitabine/tenofovir disoproxil zentiva prior to initiation of their first antiretroviral treatment regimen., the demonstration of the benefit of the combination efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavir

Docetaxel Accord European Union - English - EMA (European Medicines Agency)

docetaxel accord

accord healthcare s.l.u. - docetaxel - head and neck neoplasms, carcinoma, non-small-cell lung, adenocarcinoma, prostatic neoplasms, breast neoplasms - antineoplastic agents, - breast cancerdocetaxel accord in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.for patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.docetaxel accord in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.docetaxel accord monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.docetaxel accord in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer w